PMID- 28207913
OWN - NLM
STAT- MEDLINE
DCOM- 20180205
LR  - 20221207
IS  - 1547-3325 (Electronic)
IS  - 1040-1237 (Linking)
VI  - 29
IP  - 1
DP  - 2017 Feb
TI  - Differentiating residual symptoms of depression from adverse events among 
      patients initiating treatment with an antidepressant.
PG  - 28-34
AB  - BACKGROUND: In treated patients with major depressive disorder (MDD), residual 
      symptoms are common and challenging to disentangle from possible antidepressant 
      side effects. Our objective was to prospectively differentiate between rates of 
      residual symptoms and treatment-emergent side effects. METHODS: Participants in 
      an episode of MDD were enrolled in a 6-week trial of an antidepressant. 
      Assessments occurred at baseline and after 6 weeks of treatment, using the Quick 
      Inventory of Depressive Symptomatology Self-Report (QIDS-SR) and the 
      Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire 
      (MGH CPFQ). Among treatment responders, residual symptoms were those that 
      remained the same or improved. Side effects were defined as newly emergent or 
      worsening symptoms. RESULTS: Of 403 participants, 284 completed (70.5%) the 
      trial; 93 (32.7%) were treatment responders. Residual symptoms were common and 
      represented a substantially greater burden than side effects at end point. This 
      was true across symptoms of depression broadly, as captured by items with the 
      QIDS-SR and the MGH CPFQ. CONCLUSIONS: Prospective assessment is crucial to 
      discriminate between residual symptoms and side effects during antidepressant 
      treatment. This study demonstrated that after 6 weeks of active treatment, 
      symptoms are likely to persist despite response to treatment and are much less 
      likely to represent side effects of medication treatment.
FAU - Freeman, Marlene P
AU  - Freeman MP
AD  - Clinical Trials Network and Institute Massachusetts General Hospital, Boston, MA, 
      USA. E-mail: mfreeman@partners.org.
FAU - Fisher, Lauren
AU  - Fisher L
FAU - Clain, Alisabet
AU  - Clain A
FAU - Rabbitt, Richard
AU  - Rabbitt R
FAU - Pooley, James
AU  - Pooley J
FAU - Baer, Lee
AU  - Baer L
FAU - Fava, Maurizio
AU  - Fava M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Ann Clin Psychiatry
JT  - Annals of clinical psychiatry : official journal of the American Academy of 
      Clinical Psychiatrists
JID - 8911021
RN  - 0 (Serotonin Uptake Inhibitors)
RN  - 0DHU5B8D6V (Citalopram)
SB  - IM
MH  - Adult
MH  - Citalopram/*adverse effects/*therapeutic use
MH  - Depressive Disorder, Major/*drug therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Prospective Studies
MH  - Psychiatric Status Rating Scales/statistics & numerical data
MH  - Self Report
MH  - Selective Serotonin Reuptake Inhibitors/*therapeutic use
MH  - Surveys and Questionnaires
EDAT- 2017/02/17 06:00
MHDA- 2018/02/06 06:00
CRDT- 2017/02/17 06:00
PHST- 2017/02/17 06:00 [entrez]
PHST- 2017/02/17 06:00 [pubmed]
PHST- 2018/02/06 06:00 [medline]
AID - acp_2901c [pii]
PST - ppublish
SO  - Ann Clin Psychiatry. 2017 Feb;29(1):28-34.